SCHEMBL4953591

SCHEMBL4953591

Oc1ccc2c(Br)cccc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.60
GRM5 P41594 1/20 0.46
KCNH2 Q12809 1/20 0.46
GUSB P08236 1/20 0.40
NQO2 P16083 3/20 0.37
CYP1A2 P05177 2/20 0.37
CDK9 P50750 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK2 Q92630 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
ACHE P22303 1/20 0.35
GRM2 Q14416 1/20 0.35
TYMS P04818 1/20 0.35
NOS1 P29475 1/20 0.34
AXL P30530 1/20 0.34
C1R P00736 1/20 0.34
KMT2A Q03164 1/20 0.34
PRNP P04156 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
SLC9A1 P19634 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375911 1.00 BACE1 (0.60) BACE1GRM5KCNH2GUSBNQO2
SCHEMBL28415013 0.78 BACE1 (0.64) BACE1GRM5KCNH2GUSBNQO2
SCHEMBL4615123 0.78 ACHE (0.48) BACE1GUSBNQO2CYP1A2ACHE
SCHEMBL31756394 0.75 PDE7A (0.36) BACE1CYP1A2ACHETYMSC1R
SCHEMBL18493817 0.75 ALDH1A1 (0.50) BACE1KCNH2NQO2CYP1A2ACHE
SCHEMBL25330955 0.75 NQO2 (0.43) BACE1KCNH2GUSBNQO2CYP1A2
SCHEMBL18995270 0.75 BACE1 (0.60) BACE1GRM5KCNH2GUSBNQO2
SCHEMBL7045373 0.75 CYP1A2 (0.42) GUSBNQO2CYP1A2CDK9DYRK1A
SCHEMBL3067674 0.75 BACE1 (1.00) BACE1GRM5KCNH2NQO2ACHE
SCHEMBL707745 0.75 BACE1 (0.66) BACE1GRM5KCNH2GUSBNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP disclosed
EP-2766344-B1 EP1 RECEPTOR LIGANDS ESTEVE LABOR DR (ES) 2017-05-03 EP disclosed
US-9518015-B2 EP1 receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-12-13 US disclosed
CN-104220422-A Ep1 receptor ligands ESTEVE LABOR DR 2014-12-17 CN disclosed
US-20140323475-A1 EP1 RECEPTOR LIGANDS ESTEVE PHARMACEUTICALS, S.A. (ES) 2014-10-30 US disclosed
EP-2766344-A1 EP1 RECEPTOR LIGANDS Laboratorios Del. Dr. Esteve, S.A. (ES) 2014-08-20 EP disclosed
WO-2013037960-A1 EP1 RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-03-21 WO disclosed
WO-2009002955-A1 PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID SANOFI-AVENTIS U.S. LLC (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323475-A1 EP1 RECEPTOR LIGANDS PTGER1, PTGER2, PTGIR BACE1 3055/4885GRM5 187/4885KCNH2 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.